Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHYF) Revenue (2019 - 2025)

Historic Revenue for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to $3.2 million.

  • Innate Pharma's Revenue fell 6447.19% to $3.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $81.4 million, marking a year-over-year decrease of 9983.93%. This contributed to the annual value of $21.5 million for FY2024, which is 6758.06% down from last year.
  • Per Innate Pharma's latest filing, its Revenue stood at $3.2 million for Q2 2025, which was down 6447.19% from $13.5 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Revenue ranged from a high of $50.6 billion in Q4 2022 and a low of $3.2 million during Q2 2025
  • Moreover, its 5-year median value for Revenue was $16.2 million (2021), whereas its average is $6.3 billion.
  • Per our database at Business Quant, Innate Pharma's Revenue skyrocketed by 36497413.0% in 2022 and then tumbled by 9988.96% in 2023.
  • Innate Pharma's Revenue (Quarter) stood at $13.9 million in 2021, then soared by 364974.13% to $50.6 billion in 2022, then crashed by 99.89% to $55.8 million in 2023, then crashed by 75.85% to $13.5 million in 2024, then crashed by 76.48% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q2 2025, $13.5 million for Q4 2024, and $8.9 million during Q2 2024.